Cognitive disorders

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Neurological disorders, Cognitive disorders, Psychiatric diagnosis, Neuroscience, Granulin, Dementia, Frontal lobe, Frontotemporal dementia, Amyotrophic lateral sclerosis, FTD

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) onFriday, June 11, 2021 at10:30 a.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) onFriday, June 11, 2021 at10:30 a.m.
  • Alector management will also provide an overview of the ongoing development program for AL001 in FTD-GRN.
  • A replay will be available on the Alector website for 30 days following the event.
  • AL001 has received Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN from theU.S.

Agitation in Delirium Management Market - Global Size, Share, Outlook, and Opportunity Analysis, 2016-2020 & 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
General Health, Pharmaceutical, Health, Mental health, Medical specialties, Intensive care medicine, Medicine, Clinical medicine, Psychiatric diagnosis, Cognitive disorders, Delirium, Antipsychotic, Intensive care unit, Typical antipsychotic, E. Wesley Ely

The "Agitation in Delirium Management Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Agitation in Delirium Management Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an in-depth analysis of global agitation in delirium management market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
    Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients.
  • For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU).
  • Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market.

Groundbreaking Alzheimer's Disease Blood Test Subject of Upcoming Webinar

Retrieved on: 
Thursday, May 20, 2021
Cognitive disorders, Branches of biology, Learning disabilities, Psychiatric diagnosis, Abnormal psychology, Alzheimer's disease, Dementia, Neuroscience, Psychiatry

Diagnosing Alzheimer\'s Disease: A Groundbreaking New Blood Test is free and open to the public.

Key Points: 
  • Diagnosing Alzheimer\'s Disease: A Groundbreaking New Blood Test is free and open to the public.
  • Registration is required.\nCo-creator of first blood test to diagnose Alzheimer\'s to talk live about groundbreaking new test.\nDr.
  • Holtzman is a co-inventor of a new blood test, PrecivityAD, designed to assist physicians with diagnosing Alzheimer\'s disease.
  • Its funded initiatives have been responsible for several key breakthroughs including the groundbreaking "Alzheimer\'s in a Dish" study.

New study finds that Americans believe daylight is essential to their wellbeing, yet they spend most of their time indoors

Retrieved on: 
Thursday, May 20, 2021
Psychiatric diagnosis, Cognitive disorders, Branches of biology, Learning disabilities, Mind, Psychiatry, Abnormal psychology, Dementia, Alzheimer's disease, Sleep, Productivity

The study revealed that 83% of respondents agree that natural daylight is important for good health, affecting things such as sleep cycles, mental focus, and worker productivity.

Key Points: 
  • The study revealed that 83% of respondents agree that natural daylight is important for good health, affecting things such as sleep cycles, mental focus, and worker productivity.
  • Government studies put the numbers even higher, revealing that most Americans now spend 93% of their lives indoors[1].\nThe survey\'s findings around light\'s impact on sleep were particularly telling.
  • For the elderly, respondents believe light can improve symptoms of dementia and Alzheimer\'s, with more than 42% of respondents agreeing.
  • And two-thirds of adults (67%) believe natural light improves worker productivity.\nAll figures, unless otherwise stated, are from YouGov Plc.

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

Retrieved on: 
Wednesday, May 19, 2021
Psychiatry, Psychiatric diagnosis, Abnormal psychology, Receptor antagonists, Psychopathology, Cognitive disorders, Atypical antipsychotics, Mood stabilizers, Bipolar disorder, Dementia, Schizophrenia

The FDA has assigned a Prescription Drug User Fee Act (\xe2\x80\x9cPDUFA\xe2\x80\x9d) target action date of January 5, 2022.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (\xe2\x80\x9cPDUFA\xe2\x80\x9d) target action date of January 5, 2022.
  • On average, patients with these conditions experience more than a dozen episodes per year, the majority requiring pharmacologic treatment.
  • BXCL501 has been granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders and dementia.
  • The Company recently received acceptance of its New Drug Application for BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.

Premier Game Table Brand, 11 Ravens, Announces New Limited Edition Wayne Gretzky (aka "The Great One") Stealth Table

Retrieved on: 
Tuesday, May 18, 2021
Food and drink, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Foods, Branches of biology, Dementia, Alzheimer's disease, Cake, Icing, Table

SAEF offers \'table tennis therapy\' to enhance the lives of individuals with Alzheimer\'s and other forms of dementia through specialized play.

Key Points: 
  • SAEF offers \'table tennis therapy\' to enhance the lives of individuals with Alzheimer\'s and other forms of dementia through specialized play.
  • The ice hockey legend customized the Stealth Table design to complement his home and stay active with his sports-oriented family.\n"Collaborations are a driving force for 11 Ravens.
  • "The fact that we are able to share the same passion for this game is icing on the cake.
  • "\n11 Ravens tables can be found in the most luxurious homes and hotels around the world.

Headlands Research Continues its Rapid Expansion with the Acquisition of Summit Research Network and the Launch of its Fourth Horizons Site

Retrieved on: 
Thursday, May 13, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Branches of biology, Cognition, Dementia, Alzheimer's disease, Research site

b'SAN FRANCISCO, May 13, 2021 (GLOBE NEWSWIRE) -- Headlands Research ( www.headlandsresearch.com ), a global next-generation clinical research site organization, today announced its acquisition of Summit Research Network in Portland, Oregon.

Key Points: 
  • b'SAN FRANCISCO, May 13, 2021 (GLOBE NEWSWIRE) -- Headlands Research ( www.headlandsresearch.com ), a global next-generation clinical research site organization, today announced its acquisition of Summit Research Network in Portland, Oregon.
  • The acquisition follows Headlands\xe2\x80\x99 recent addition of Artemis Institute for Clinical Research in February of this year.
  • Coupled with the new acquisition, Headlands Research also launched its fourth Horizons site in Scottsdale, AZ, which expands its global network to 15 clinical trial sites.\nSummit Research Network, founded in 1976, is dedicated to improving medical treatment by conducting high quality scientific research and patient care.
  • Summit Research Network specializes in the areas of psychiatry, dementia and other age-related memory conditions such as Alzheimer\xe2\x80\x99s and Lewy Bodies, and operates a specialized Memory Health Center ( www.memoryhealthcenter.com ).

Trial First to Show Improvements in Alzheimer's Patients

Retrieved on: 
Thursday, May 13, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Bredesen, Dementia, Toups, Psychiatry, Cognition

Kat Toups, Ann Hathaway, and Deborah Gordonalong with Dr. Dale Bredesen, a professor at UCLA.\nTheir proof-of-concept trial included 25 participants, aged 50 to 76, all with MCI (pre-Alzheimer\'s) or early-stage dementia.

Key Points: 
  • Kat Toups, Ann Hathaway, and Deborah Gordonalong with Dr. Dale Bredesen, a professor at UCLA.\nTheir proof-of-concept trial included 25 participants, aged 50 to 76, all with MCI (pre-Alzheimer\'s) or early-stage dementia.
  • The report concluded that a larger, randomized controlled trial is warranted, and this follow-up study is already in the works.
  • ; Henrianna Chung; Alan Boyd; Benjamin Hill, Ph.D.; Mouna Attarha, Ph.D.; Won Jong Chwa; Michael Jarrett, Ph.D; and Dale Bredesen, M.D.
  • This study was supported with funding by the Four Winds Foundation; performed in collaboration with QuesGen Systems, Inc. CRO.

Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer's Disease 7 Years Before Symptoms Occur

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Biology, Biomarkers, Psychiatric diagnosis, Life sciences, Cognitive disorders, Learning disabilities, Dementia, Alzheimer's disease

The new study results are being presented today at the 2021 Alzheimer\'s Association International Conference (AAIC) Satellite Symposium .

Key Points: 
  • The new study results are being presented today at the 2021 Alzheimer\'s Association International Conference (AAIC) Satellite Symposium .
  • Additionally, the prognostic performance of the Diadem biomarker test was superior to covariate measures including age, gender, and APOE-related genetic susceptibility, either alone or in combination with amyloid status.
  • The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer\'s disease.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer\'s prognostic via a global launch in collaboration with strategic partners.

New Report Describes Better Framework for Assessing the Value of Alzheimer's Therapies

Retrieved on: 
Wednesday, May 12, 2021
Health Economics, Health, Health care quality, Articles, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Quality-adjusted life year, Alzheimer's disease

b'WASHINGTON, May 12, 2021 /PRNewswire/ --Today the Alliance for Aging Research released a report, " Assessing the Value of Therapies in Alzheimer\'s Disease: Considerations to create a practical approach to value ," which the Alliance had commissioned from Milliman .

Key Points: 
  • b'WASHINGTON, May 12, 2021 /PRNewswire/ --Today the Alliance for Aging Research released a report, " Assessing the Value of Therapies in Alzheimer\'s Disease: Considerations to create a practical approach to value ," which the Alliance had commissioned from Milliman .
  • The report outlines a new framework for assessing the value of Alzheimer\'s treatments and describes how the traditional approach to value assessment for therapeutics fails to address the challenges posed by Alzheimer\'s disease (AD) and suggests principles to create an alternative, equitable value assessment framework.
  • The report explores technical issues with the use of quality adjusted life years (QALYs) that render the traditional approach problematic.
  • The QALY has significant limitations when dealing with complex diseases such as AD, as they do not recognize value driven by public health improvement, transformation, or even societal value.